KRAS and colorectal carcinoma: In CRC, CD16-CAR T-cells combined with cetuximab decreased the viability of KRAS-mutated HCT116 CRC cells in vitro, decreased tumor growth in a SCID mouse model, and increased disease-free survival (229).